Pathogenic role of acyl coenzyme A binding protein (ACBP) in Cushing’s syndrome

Archive ouverte

Pan, Hui | Tian, Ai-Ling | Chen, Hui | Xia, Yifan | Sauvat, Allan | Moriceau, Stephanie | Lambertucci, Flavia | Motiño, Omar | Zhao, Liwei | Liu, Peng | Mao, Misha | Li, Sijing | Zhang, Shuai | Joseph, Adrien | Durand, Sylvère | Aprahamian, Fanny | Luo, Zeyu | Ou, Yang | Shen, Zhe | Xue, Enfu | Pan, Yuhong | Carbonnier, Vincent | Stoll, Gautier | Forveille, Sabrina | Leduc, Marion | Cerrato, Giulia | Cerone, Alexandra | Maiuri, Maria, Chiara | Castinetti, Frederic | Brue, Thierry | Wang, Hongsheng | Ma, Yuting | Martins, Isabelle | Kepp, Oliver | Kroemer, Guido

Edité par CCSD ; Nature Publishing Group -

International audience. Cushing’s syndrome is caused by an elevation of endogenous orpharmacologically administered glucocorticoids. Acyl coenzyme A bindingprotein (ACBP, encoded by the gene diazepam binding inhibitor, Dbi)stimulates food intake and lipo-anabolic reactions. Here we found thatplasma ACBP/DBI concentrations were elevated in patients and mice withCushing’s syndrome. We used several methods for ACBP/DBI inhibition inmice, namely, (1) induction of ACBP/DBI autoantibodies, (2) injection of aneutralizing monoclonal antibody, (3) body-wide or hepatocyte-specificknockout of the Dbi gene, (4) mutation of the ACBP/DBI receptor Gabrg2and (5) injections of triiodothyronine or (6) the thyroid hormone receptor-βagonist resmetirom to block Dbi transcription. These six approachesabolished manifestations of Cushing’s syndrome such as increased foodintake, weight gain, excessive adiposity, liver d am age, hyp ertr ig lyce-ridaemia and type 2 diabetes. In conclusion, it appears that ACBP/DBIconstitutes an actionable target that is causally involved in the developmentof Cushing’s syndrome.

Suggestions

Du même auteur

Acyl-CoA binding protein for the experimental treatment of anorexia

Archive ouverte | Chen, Hui | CCSD

International audience. Extracellular acyl-coenzyme A binding protein [ACBP encoded by diazepam binding inhibitor (DBI)] is a phylogenetically ancient appetite stimulator that is secreted in a nonconventional, autop...

BCL2 Inhibition Reveals a Dendritic Cell–Specific Immune Checkpoint That Controls Tumor Immunosurveillance

Archive ouverte | Zhao, Liwei | CCSD

International audience. Abstract We developed a phenotypic screening platform for the functional exploration of dendritic cells (DC). Here, we report a genome-wide CRISPR screen that revealed BCL2 as an endogenous i...

Anticancer effects of ikarugamycin and astemizole identified in a screen for stimulators of cellular immune responses

Archive ouverte | Zhang, Shuai | CCSD

International audience. Background Most immunotherapies approved for clinical use rely on the use of recombinant proteins and cell-based approaches, rendering their manufacturing expensive and logistics onerous. The...

Chargement des enrichissements...